Anthos Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
21
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1900
- Registration Number
- NCT05712200
- Locations
- 🇺🇸
Anthos Investigative Site 1040, Birmingham, Alabama, United States
🇺🇸Anthos Investigative Site 1041, Mobile, Alabama, United States
🇺🇸Anthos Investigative Site 1089, Gilbert, Arizona, United States
Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 705
- Registration Number
- NCT05421533
- Locations
- 🇬🇧
Anthos Investigate Site, Middlesex, United Kingdom
🇬🇧Anthos Investigative Site, Barry, Vale Of Glamorgan, United Kingdom
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- Conditions
- Venous ThromboembolismDeep Venous ThrombosisPulmonary Embolism
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1020
- Registration Number
- NCT05171075
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Washington DC VAMC, Washington, District of Columbia, United States
🇺🇸University of Miami Health System/Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- Conditions
- Deep Venous ThrombosisPulmonary EmbolismVenous Thromboembolism
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1655
- Registration Number
- NCT05171049
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸VA Connecticut Healthcare System, West Haven, Connecticut, United States
🇺🇸Washington DC VAMC, Washington, District of Columbia, United States
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
- Conditions
- Atrial Fibrillation (AF)Stroke
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1287
- Registration Number
- NCT04755283
- Locations
- 🇨🇳
Anthos Investigative Site, Tiachung, TXG, Taiwan
🇭🇺Anthos Investigative Site (4002), Nyíregyháza, SZ, Hungary
🇭🇺Anthos Investigative Site (4003), Nyíregyháza, SZ, Hungary
- Prev
- 1
- 2
- Next